The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...

Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the therapy for transthyretin ...

One reason for the fall could be the competitive threat posed by BridgeBio’s acoramidis, which demonstrated a 42% reduction in all-cause mortality and recurrent cardiovascular events in its ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) recently announced that the U.S. Food and Drug Administration (FDA) has approved attruby™ (acoramidis), a near-complete stabilizer of transthyretin (TTR), for the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.